Skip to main content

Table 1 Background characteristics by study group*

From: Testing a home-based model of care using misoprostol for prevention and treatment of postpartum hemorrhage: results from a randomized placebo-controlled trial conducted in Badakhshan province, Afghanistan

 Misoprostol
(800mcg SL)
(n = 40)
Placebo
(n = 39)
Age, mean ± SD24.7 ± 4.826.0 ± 5.5
Parity, mean ± SD3.1 ± 1.92.9 ± 1.8
Woman categorized as literate8 (20.0)8 (20.5)
Iron folate tablets taken during pregnancy38 (95.0)38 (100) a
Duration during which iron folate tablets were taken (months), mean + SD1.9 ± 1.52.4 ± 2.3 a
Pre-delivery Hb (g/dL) b
 mean ± SD12.4 ± 1.412.1 ± 1.8
 (range)(9.0–15.9)(7.7–15.8)
  1. Abbreviations: Hb hemoglobin, SL sublingual
  2. * Data presented as n (%) unless otherwise stated
  3. an = 38; data on iron folate missing for one case in the placebo arm
  4. b In six cases (misoprostol, n = 1; placebo, n = 5) pre-delivery Hb was not measured due to enrollment in the study at the time of the delivery